About the Urothelial Cancer working party

The European Association of Urology has recently supported the development of expert groups of young academic urologists with the purpose of boosting research activity in some critical areas of urology and improving academic collaboration among different centres in Europe. The expert groups aim at scientific cooperation, study design or other scientific output. The Urothelial Cancer working party is open to European non-urologists with an interest in the management of Urothelial Carcinoma of the Upper and Lower Tract in order to fully cover the disease in a multidisciplinary fashion.

Aims of the Urothelial Cancer working party

The chief aim of our working party is to bring young academic urologists practicing in Europe with a chief interest in the management of Urothelial Carcinoma together and promote active collaboration between them. Our group also wishes to include young academic non-urologists (i.e. radiologists, radiation oncologists and medical oncologists) practicing in Europe with a chief interest in the management of Urothelial Carcinoma, in order to approach the disease from many different professional angles. Another goal is to merge already existing retrospective multi-institutional databases and create prospective multi-institutional databases and registry studies.

Within the EAU, our group wishes to actively participate in the revision process of the EAU Guideline on Non-Muscle- Invasive, Muscle-Invasive and Upper Tract Urothelial Carcinoma.

Projects and plans for the future

Prospective original studies:

  • Prospective evaluation of the impact of smoking exposure at the time of    diagnosis in patients with Muscle-Invasive Bladder Cancer treated with radical cystectomy and pelvic lymphadenectomy.
  • Prospective evaluation of the impact of smoking exposure at the time of diagnosis in patients with Upper Tract Urothelial Carcinoma treated with radical nephroureterectomy.
  • Prospective evaluation of the quality of life after radical cystectomy for Muscle-Invasive Bladder Cancer using translated validated questionnaires.

Retrospective original studies:

  • Multicentre retrospective validation of the T1 substaging (micro/extended) in patients with Non-Muscle Invasive Bladder Cancer treated with TUR and adjuvant BCG.
  • Prognostic factors and risk groups in T1G3 Non-Muscle-Invasive Bladder Cancer patients initially treated with bacillus calmette-guérin: results of a retrospective multicentre study of 2451 patients.
  • Impact of restaging TUR in T1G3 Non-Muscle-Invasive Bladder Cancer patients initially treated with bacillus calmette-guérin.
  • Impact of postchemotherapy lymphadenectomy on outcome of patients with clinical node-positive Metastatic Bladder Cancer.
  • Evaluation of the perioperative complication rates and clinical outcomes of patients with Muscle-Invasive Bladder Cancer treated with radical cystectomy with a previous history of abdominal radiation therapy.
  • Management of Bladder Cancer in diverticula.

Review articles:

  • Systematic review and meta-analysis of the clinical, pathological and oncological outcomes associated with robotic-assisted radical cystectomy for Muscle-Invasive Bladder Cancer.
  • Impact of smoking exposure on oncological outcomes of patients with Bladder Cancer.

Surveys:

  • Urologist’s role in smoking cessation.• Practice patterns among European urologists of immediate postoperative   instillation of chemotherapy after radical nephroureterectomy for Upper Tract Urothelial Carcinoma.

Board YAU Working Group Urothelial

E. Xylinas

Paris (FR)
Chairman

A. Aziz

Rostock (DE)
Member

R. Seiler

Liebefeld (CH)
Member

C. Poyet

Zürich (CH)
Member

A. Necchi

Milan (IT)
Member

K. Hendricksen

Noordwijk (NL)
Member

M. Moschini

Luzern (CH)
Member

A. Noon

Sheffield (GB)
Member

F. Roghmann

()
Member

P. Sargos

Bordeaux (FR)
Member

M. Rink

Hamburg (DE)
Member

F-C. Von Rundstedt

Jena (DE)
Member

M.W. Vetterlein

Hamburg (DE)
Member